| Project/Area Number |
26670486
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
MORIMOTO CHIKAO 順天堂大学, 医学(系)研究科(研究院), 客員教授 (30119028)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IWATA Satoshi 順天堂大学, 医学部, 非常勤講師 (00396871)
OHNUMA Kei 順天堂大学, 医学部, 准教授 (10396872)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | MERS感染症 / コロナウイルス / CD26/DPPⅣ / 重症呼吸器感染症 / ヒト化CD26抗体 / CD26単クローン抗体 / アポトーシス / エピトープ / (1) MERS感染症 / トランスジェニックマウス / ① MERS感染症 / ② コロナウイルス / CD26 / ④ 重症呼吸器感染症 / ⑤ ヒト化CD26抗体 / ⑦ CD26単クローン抗体 |
|---|
| Outline of Final Research Achievements |
We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb also significantly inhibited infection. These findings indicate that both 2F9 and humanized Mab are potential therapeutic agents for MERS infection.
MERS infects human bronchial epithelial Calu-3 cells as well as CD26 Jurkat T lymphocyte cells. Unlike severe acute respiratory syndrome (SARS)-CoV, which exclusively infects and releases through the apical route, this virus can do so through either side of polarized Calu-3 cells. Infection results in profound apoptosis irrespective of its production of titers that are lower than those of SARS-CoV. Together, our results provide new insights into the dissemination and pathogenesis of MERS-CoV and may cause in immune defects since it infected in human CD26 T cells.
|
